Andrew Chan

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis

Muhammad Aslam, Sudhakar Reddy Kalluri, Lucas Schirmer et al. · New England Journal of Medicine · 2012 · 339 citations · Full text

Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis

Stephanie C. Steinberg, Richard Faris, Cyril F. Chang et al. · Clinical Drug Investigation · 2010 · 244 citations

Immunology, Clinical Trials, Clinical Neurology +5

Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder

Marius Ringelstein, Ilya Ayzenberg, Jens Harmel et al. · JAMA Neurology · 2015 · 236 citations

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Matthias B. Moor, Franziska Suter‐Riniker, Michael P. Horn et al. · The Lancet Rheumatology · 2021 · 208 citations · Full text